Novoseven use in a non-cardiac pediatric ECMO patient with uncontrolled bleeding

Journal of Extra-Corporeal Technology

Volumn 40, Issue 2, 2008, Pages 123-126

  Preston, Thomas J ^a,b   Olshove, Vincent F ^a   Ayad, Onsy ^a   Nicol, Kathleen K ^a   Riley, Jeffrey B ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b 700 Children's Drive   (United States)

Author keywords

Bleeding; Extracorporeal membrane oxygenation; Factor VIIa; NovoSeven

Indexed keywords

AMINOCAPROIC ACID; AMINOCARPOIC ACID; BUDESONIDE; FIBRINOLYTIC AGENT; FUROSEMIDE; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SALBUTAMOL; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; BLOOD CLOT; BLOOD TRANSFUSION; CASE REPORT; CONFERENCE PAPER; EXTRACORPOREAL OXYGENATION; HEMOSTASIS; HUMAN; INFANT; LABORATORY TEST; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; PULMONARY HYPERTENSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; THROMBOSIS; VIRUS INFECTION; ARTICLE; RESPIRATORY FAILURE;

COAGULANTS; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIIA; HEMORRHAGE; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; RESPIRATORY INSUFFICIENCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 54449099578     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005;6:473-6.
2. Murkin JM. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anesth. 2002;49:521-6.
3. Dominguez TE, Mitchell M, Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2005;6:348-51.
4. Diprose P, Herbertson MJ, Shaughnessy DO, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anesth. 2005;95:596-602.
5. Brose S, Sirbu H, Engel M, Kuhlen R, Autschbach R. Successful use of recombinant factor VIIa in a patient with intractable bleeding during extra-corporeal membrane oxygenation. Thorac Cardiovasc Surg. 2005;53:389-90.
6. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007;84:161-9.
7. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002;124:852-4.
8. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-8.